Akoya Biosciences, Inc. (AKYA)
After hours:
| Previous Close | 2.8700 |
| Open | 2.8700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.8000 - 2.8900 |
| 52 Week Range | 1.8800 - 6.3100 |
| Volume | |
| Avg. Volume | 152,409 |
| Market Cap | 138.599M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1700 |
| Earnings Date | Nov 06, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
GlobeNewswireAkoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust Akoya’s platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers predicting treatment success MARLBOROUGH, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that the company’s PhenoCycle
- GlobeNewswire
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya’s board. Mr. Mendel has served as a member of Akoya’s board of directors since June 2021 and has over 30 years of financial and operational management experience. “I am thrilled to cont
